Gabelli Funds LLC Sells 16,750 Shares of Henry Schein, Inc. $HSIC

Gabelli Funds LLC cut its stake in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 4.8% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 329,336 shares of the company’s stock after selling 16,750 shares during the quarter. Gabelli Funds LLC owned approximately 0.27% of Henry Schein worth $24,058,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. ANTIPODES PARTNERS Ltd acquired a new position in shares of Henry Schein in the second quarter worth approximately $43,000. Steph & Co. acquired a new stake in Henry Schein during the 2nd quarter valued at approximately $44,000. CX Institutional raised its holdings in Henry Schein by 107.3% during the 2nd quarter. CX Institutional now owns 651 shares of the company’s stock worth $48,000 after purchasing an additional 337 shares during the last quarter. TD Private Client Wealth LLC raised its stake in Henry Schein by 103.0% during the second quarter. TD Private Client Wealth LLC now owns 668 shares of the company’s stock worth $49,000 after buying an additional 339 shares during the last quarter. Finally, Evelyn Partners Investment Management Services Ltd acquired a new position in shares of Henry Schein in the 2nd quarter valued at about $62,000. Institutional investors and hedge funds own 96.62% of the company’s stock.

Henry Schein Price Performance

Shares of NASDAQ:HSIC opened at $73.62 on Monday. The firm has a market capitalization of $8.67 billion, a PE ratio of 23.30, a P/E/G ratio of 2.26 and a beta of 0.89. The company has a quick ratio of 0.79, a current ratio of 1.40 and a debt-to-equity ratio of 0.54. The company has a 50-day moving average price of $68.30 and a two-hundred day moving average price of $69.42. Henry Schein, Inc. has a twelve month low of $60.56 and a twelve month high of $82.49.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings results on Tuesday, November 4th. The company reported $1.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.27 by $0.11. The company had revenue of $3.34 billion for the quarter, compared to analyst estimates of $3.28 billion. Henry Schein had a net margin of 3.02% and a return on equity of 14.76%. Henry Schein has set its FY 2025 guidance at 4.880-4.960 EPS. Equities analysts forecast that Henry Schein, Inc. will post 4.74 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on HSIC shares. Wells Fargo & Company upped their price target on Henry Schein from $70.00 to $76.00 and gave the stock an “equal weight” rating in a research note on Wednesday, November 5th. Barrington Research set a $79.00 target price on Henry Schein and gave the company an “outperform” rating in a research report on Wednesday, November 5th. Weiss Ratings reiterated a “hold (c)” rating on shares of Henry Schein in a research note on Thursday. Wall Street Zen raised Henry Schein from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Henry Schein from $76.00 to $78.00 and gave the stock an “overweight” rating in a report on Wednesday, November 5th. Five investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $76.17.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.